MedTrace Logo

A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma

NCT00592579 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-02-26

No results posted yet for this study

Summary

The purpose of the study is to determine the safety and effectiveness of providing 2-methoxyestradiol to patients with plateau phase or relapsed multiple myeloma. Information regarding trough 2ME2 levels will also be collected.

Conditions

  • Relapsed Multiple Myeloma
  • Plateau Phase Multiple Myeloma

Interventions

DRUG

2-methoxyestradiol

800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.

Sponsors & Collaborators

  • CASI Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00592579 on ClinicalTrials.gov